GlobeNewswire by notified

CDR-Life Presents Findings from Two Studies in Preparation of Phase 1 Trial with Immunotherapy CDR404 for Treatment of Solid Tumors at SITC 2023


Therapeutic potential of CDR404, as a first-of-its-kind precision immunotherapy for HLA-A*02:01+ patients with MAGE-A4+ squamous non-small cell lung carcinoma (SQ-NSCLC)

Development of a Quantitative Systems Pharmacology (QSP) model to facilitate discovery of safe and efficacious doses for upcoming Phase 1 trial

ZÜRICH, Switzerland, Nov. 03, 2023 (GLOBE NEWSWIRE) -- CDR-Life Inc., in the run-up to initiation of its first Phase 1 clinical trial, presented two posters for CDR404, a first-of-its-kind, antibody-based, bivalent & bispecific MAGE-A4 T-cell engager (TCE) targeting MAGE-A4, an intracellular cancer protein with expression in several frequent and difficult to treat solid tumors, at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting.

“The absence of actionable genetic alterations makes SQ-NSCLC a difficult-to-treat cancer after relapse from immune checkpoint blockade. The demonstration of high MAGE-A4 protein expression in SQ-NSCLC and potent preclinical cytotoxicity of CDR404, highlights the therapeutic promise of CDR404 in HLA-A*02:01+ patients with SQ-NSCLC. Results from the second presentation show that leveraging the QSP model for the prediction of CDR404 doses that are likely to be safe and efficacious will enable CDR-Life to select the most effective dose to carry forward into a future registrational study,” said Swethajit Biswas, M.D., Ph.D., Chief Medical Officer at CDR-Life.

“These milestones underscore the continued advancement of CDR404’s potential as an off-the-shelf precision immunotherapy for MAGE-A4+ solid tumors. The unique Fab-(scFv)2 molecular format and CD3 binding properties of CDR404 is very different compared to previous T-cell engagers which have targeted MAGE-A4+ tumors, thereby optimizing the probability-of-success in the clinic,” Dr. Biswas concluded.

Poster presentation highlights include:

Abstract 1397

  • SQ-NSCLC had the highest MAGE-A4 mRNA expression levels among solid cancers in the TCGA database.
  • Immunohistochemistry showed positive MAGE-A4 staining in 28/50 SQ-NSCLC samples.
  • Treatment with four different doses of CDR404 induced complete tumor regression in the in vivo SQ-NSCLC NCI-H1703 xenograft model.

Abstract 195

  • The QSP model builds a preliminary understanding of the relationship between MAGE-A4 expression and intra-tumor T-cell density in determining CDR404 anti-tumor activity.
  • The QSP model predicted doses of CDR404 which might have the most favorable benefit-risk profile for patients in the Phase 1 trial.

Poster Presentation Details:

Title: CDR404, an antibody-based bispecific & bivalent T-cell engager targeted against MAGE-A4, for Squamous Non-Small Cell Lung Cancer (SQ-NSCLC)
Abstract Number: 1397
Presentation Date: Friday, November 3, 2023
Presentation Time: 12:00 p.m. - 1:30 p.m. PDT

Title: Overcoming the dose-response prediction limitation from bench to clinic for T-cell engagers: Using Quantitative Systems Pharmacology (QSP) modeling in the development of CDR404 for solid tumors
Abstract Number: 195
Presentation Date: Friday, November 3, 2023
Presentation Time: 12:00 p.m. - 1:30 p.m. PDT

About CDR-Life

CDR-Life is developing highly specific antibody therapeutics to target intracellular proteins presented on the major histocompatibility complex (MHC). Our versatile MHC-targeted antibody platform increases access to a vast array of antigens that were not previously addressable, to develop a pipeline of first in class therapeutics across a broad range of solid tumors. With a team of proven drug development experts and backed by leading cross-Atlantic investors, we are working to redirect and activate the patient’s own immune system to eliminate their tumors.

To view this piece of content from, please give your consent at the top of this page.
To view this piece of content from, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Changes in the number of own shares held by Aktia Bank Plc28.11.2023 13:00:00 CET | Press release

Aktia Bank Plc Stock Exchange Release 28 November 2023 at 2.00 p.m. Changes in the number of own shares held by Aktia Bank Plc Aktia Bank Plc has today, based on a decision made by the company's Board of Directors, divested a total of 808 own shares held by the company to four persons as a deferred payment based on the company’s remuneration programs. The divestment of own shares is based on the authorisation by the Annual General Meeting of Shareholders held on 5 April 2023. After the above-mentioned divestments, a total of 159,538 shares remain in the company’s possession. Aktia Bank Plc Further information: Mia Smeds, Communications director, +358 44 546 0379, mia.smeds(at) Distribution: Nasdaq Helsinki Ltd Mass media Aktia is a Finnish asset manager, bank and life insurer that has been creating wealth and wellbeing from one generation to the next for 200 years. We serve our customers in digital channels everywhere and face-to-face in our offices in the Helsink

Ändringar i antalet egna aktier i Aktia Bank Abp:s besittning28.11.2023 13:00:00 CET | Pressemelding

Aktia Bank Abp Börsmeddelande 28.11.2023 kl. 14.00 Ändringar i antalet egna aktier i Aktia Bank Abp:s besittning Aktia Bank Abp har idag med stöd av ett beslut av bolagets styrelse överlåtit totalt 808 Aktia-aktier i bolagets besittning till fyra personer som betalning av uppskjutna ersättningar enligt bolagets belöningssystem. Överlåtelsen av aktier är baserad på bemyndiganden av den ordinarie bolagsstämman 5.4.2023. Efter ovan nämnda överlåtelser har bolaget sammanlagt 159 538 aktier i sin besittning. Aktia Bank Abp Mera information: Mia Smeds, kommunikationsdirektör, tfn 044 546 0379, mia.smeds(at) Distribution: Nasdaq Helsinki Oy Massmedier Aktia är en finländsk kapitalförvaltare, bank och livförsäkrare som har skapat välstånd och välfärd generation efter generation redan under 200 års tid. Vi tillhandahåller våra kunder digitala tjänster i ett flertal kanaler och ger personlig service på våra verksamhetsställen i huvudstadsregionen samt i Åbo-, Tammerfors-, V

Karolinska Developments portföljbolag Umecrine Cognition presenterar positiv effekt med golexanolon i en preklinisk modell av kolestas28.11.2023 12:44:51 CET | Pressemelding

STOCKHOLM, SVERIGE 28 november 2023. Karolinska Development AB (Nasdaq Stockholm: KDEV) meddelar att portföljbolaget Umecrine Cognition har presenterat positiva resultat från en studie med bolagets läkemedelskandidat golexanolone i en preklinisk modell av PBC-relaterad symtomologi och neuroinflammation. Resultaten indikerar en normaliserande effekt på kognitiva symtom såsom trötthet, motoriska störningar, neuroinflammation och neurala signaler. Resultaten publiceras i novemberutgåvan av den internationellt välrenommerade tidskriften Liver International. Resultaten från den prekliniska studien, som utfördes i en validerad och välkänd sjukdomsmodell av kolestas, visar att golexanolon förbättrar symtom som vanligtvis ses vid PBC. Studien visar en tydlig minskning av central trötthet, signifikanta förbättringar av korttidsminnet och normaliserande motoriska funktioner efter en 4-5 veckors lång behandling med golexanolon. ”Trötthet är högst prioriterat för symtomlindring för PBC-patienter e

Karolinska Development’s portfolio company Umecrine Cognition presents positive effects of golexanolone in a preclinical model of cholestasis28.11.2023 12:44:51 CET | Press release

STOCKHOLM, SWEDEN – November 28, 2023. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company Umecrine Cognition has presented positive results from a study of the company’s drug candidate golexanolone in a preclinical model of PBC-like symptomology and neuroinflammation. The results indicate a normalizing effect on cognitive symptoms, such as fatigue, motor impairments, neuroinflammation, and neural signaling. The results are published in the November issue of the internationally renowned journal Liver International. The results from the preclinical study, which was performed in a validated and well-known disease model of cholestasis, show that golexanolone improves symptoms generally seen in PBC. The study shows a clear reduction in central fatigue, marked improvements in short-term memory, and normalized motoric functions following a 4–5-week treatment regimen with golexanolone. “Fatigue is the highest priority of symptom relief for PBC patient

Vardagen fångad i blixtbelysning28.11.2023 12:19:36 CET | Pressemelding

Uppsala, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Lars Tunbjörk 2 dec - 28 jan 2024 Bror Hjorths Hus, Uppsala Lars Tunbjörks fotografier visas i Bror Hjorths Hus Årets sista utställning i Bror Hjorths Hus visar verk ut tre serier av den svenska fotografen Lars Tunbjörk (1956–2015). Den invigs lördag 2 december och pågår till 28 januari 2024. Pressvisning: lämpligast torsdag 30 november kl 10-14 (se mer nedan) Lars Tunbjörk skapade en helt egen fotografisk stil. Den genomsyrade alla hans bilder, oavsett om det rörde sig om foton av hemstaden Borås, det svenska landskapet och dess olika årstider, kontorsmiljöer eller modeller i Paris. Med en säregen blick, tålamod och passion dokumenterade han vardagen i skarp blixtbelysning. Lars Tunbjörks började som pressfotograf och 1982 fick han utmärkelsen Årets fotograf. Det stora genombrottet kom drygt tio år senare med fotoboken Landet utom sig – en både roande och oroande dokumentation av svensk vardag runt decennieskiftet 1990. Ett urval av dessa fot